Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Obesity and related co-morbidities are increasing worldwide and pose a serious health problem. Changes in lifestyle and diet would be the best remedies to fight obesity; however, many people will still rely on medical aid. Marine organisms have been prolific in the production of bioactive compounds for many diseases, e.g., cancer, and promise to be an excellent source for natural-derived molecules and novel nutraceuticals. Bioactive compounds with beneficial activities towards obesity have been described from diverse marine organism including marine algae, bacteria, sponges, fungi, crustaceans or fish. This Special Issue will highlight the progress in the following topics: Bioactive compounds for the treatment of obesity and obesity-related co-morbidities (diabetes, fatty liver, hyperlipidemia) from marine organisms; the isolation of novel compounds, the bioactivity screening of marine organisms and the elucidation of molecular mode of action of marine bioactive compounds.

natural compounds --- anti-obesity drugs --- high fat diet --- Ishige okamurae --- fat --- zebrafish Nile red fat metabolism assay --- physical exercise --- JAK2-STAT3 --- metabolite profiling --- obesity --- chlorophyll derivatives --- brown seaweed --- Skate skin --- PPAR? --- marine alga --- marine biodiscovery --- skate skin --- lipolytic --- leptin --- uncoupling protein 1 --- 3T3-L1 cells --- glucolipid metabolism disorder --- nutrition --- bioactivity --- chitosan oligosaccharide --- diphlorethohydroxycarmalol (DPHC) --- nutraceuticals --- whole small animal models --- high-fat diet --- adipocyte --- dyslipidemia --- bioactivity screening --- peroxisome proliferator-activated receptor gamma --- white adipose tissue --- antiobesity --- fatty liver disease --- thermal proteome profiling --- inflammation --- cyanobacteria --- Raja kenojei --- Arthrospira maxima --- cellularity --- adipocytes --- bioactive compound --- collagen peptide --- double-blind --- bisabolane-related compounds --- proliferation --- fatty acid metabolism --- cholesterol metabolism --- collagen --- randomized controlled trial --- mechanisms of action --- murine pre-adipocytes --- adipogenesis --- fucan --- marine sponges --- label-free quantitative proteomics --- diabetes --- body fat

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Mitochondria are subcellular organelles evolved by the endosymbiosis of bacteria with eukaryotic cells. They are the main source of ATP in the cell and engaged in other aspects of cell metabolism and cell function, including the regulation of ion homeostasis, cell growth, redox status, and cell signaling. Due to their central role in cell life and death, mitochondria are also involved in the pathogenesis and progression of human diseases/conditions, including neurodegenerative and cardiovascular disorders, cancer, diabetes, inflammation, and aging. However, despite the increasing number of studies, precise mechanisms whereby mitochondria are involved in the regulation of basic physiological functions, as well as their role in the cell under pathophysiological conditions, remain unknown. A lack of in-depth knowledge of the regulatory mechanisms of mitochondrial metabolism and function, as well as interplay between the factors that transform the organelle from its role in pro-survival to pro-death, have hindered the development of new mitochondria-targeted pharmacological and conditional approaches for the treatment of human diseases. This book highlights the latest achievements in elucidating the role of mitochondria under physiological conditions, in various cell/animal models of human diseases, and in patients.

Medicine --- hypoglycemia --- sodium dichloroacetate --- pyruvate dehydrogenase kinase --- pyruvate dehydrogenase --- oxidative stress --- neuron death --- cholangiocellular carcinoma --- mitochondria --- energy metabolism --- oxidative phosphorylation --- 4-HNE --- DRP1 --- ERK1/2 --- hippocampus --- JNK --- mitochondrial dynamics --- PKA --- protein phosphatases --- TUNEL --- DDE --- high-fat diet --- mitochondrial UCP2 --- ROS --- antioxidant system --- uncoupling protein --- mitochondria: energy metabolism --- lipid handling --- fatty acid oxidation --- potassium channel --- reactive oxygen species --- antioxidants --- life span --- aging --- BKCa channels --- pravastatin --- gemfibrozil --- liver --- colon --- mitochondrial function --- cyclosporin A --- mitochondria calcium buffering --- mitochondria bioenergetics --- mitochondria permeability transition pore --- inorganic phosphate --- hepatic fibrogenesis --- HtrA2/Omi --- reactive oxygen species stress --- mitochondrial homeostasis --- complex I (CI) deficiency --- metabolome and proteome profiling --- reactive oxygen species (ROS) --- respirasome assembly --- electron tunneling (ET) --- perilipin 5 --- lipid droplet --- H9c2 cardiomyoblasts --- adenine nucleotide translocase --- respiratory supercomplexes --- ETC complexes --- dentate granule cell --- epilepsy --- hyperforin --- LONP1 --- neuroprotection --- pilocarpine --- seizure --- siRNA --- cardioprotection --- mitochondrial permeability transition pores --- mitochondrial connexin 43 --- cardiolipin --- iron overload --- hepcidin --- transferrin --- ferritin --- ZIP --- inflammation --- mtDNA --- mitochondrial dysfunction --- muscle aging --- physical performance --- LHON --- Siberian population --- ancient mutation --- specific genetic background --- apoptosis --- human amniotic membrane --- mitochondrial cell death --- BAX --- BCL-2 --- tensile strength --- mitochondrial gene expression --- mtDNA transcription --- mtRNA --- post-transcriptional mtRNA processing --- dsRNA --- innate immunity --- interferon response --- amino acid neurotransmitter --- cerebellar amino acid metabolism --- hypoxia --- 2-oxoglutarate dehydrogenase --- tricarboxylic acid cycle --- heart --- cytoskeletal proteins --- mitochondrial interactions --- plectin --- tubulin beta --- signaling --- GW9662 --- ischemia reperfusion injury --- Langendorff --- myocardial --- pioglitazone --- redox state --- rosiglitazone --- TZD --- uncoupling --- ADP/ATP carrier --- KmADP --- dextran --- morphology --- cardiomyocytes --- telomere length --- telomerase activity --- development --- regeneration --- intranuclear mitochondria --- healthy cells --- electron and confocal microscopy --- signaling pathways --- ion homeostasis --- human diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.

Renal cell carcinoma. --- Kidneys --- Cancer. --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Cancer --- N-glycomapping --- n/a --- SMAD proteins --- patient survival --- pro-IL-1? --- survival prediction --- inflammation markers --- tumor migration --- prognostic factors --- practical approach --- circular RNAs in a clinico-genomic predictive model --- glycomarkers --- review --- nephrectomy --- uric acid --- VEGF inhibitors --- metabolic reprogramming --- collecting duct carcinoma --- curcumin --- metabolome profiling --- identification of circular RNAs --- IL-2 --- experimental validation of circular RNA --- Raf/MEK/ERK --- HOT --- PI3K/Akt/mTOR --- pentose phosphate pathway --- kidney cancer --- LOT --- mutation --- RCC --- polybromo-1 --- pale cell --- MMP-9 --- gene expression --- recurrence free survival --- chromosomal loss --- IL-1? --- chronic kidney disease --- glutathione transferase omega 2 --- label-free --- glutathione transferase omega 1 --- emerging entity --- copy number alteration --- FOXO3 --- predictive role --- tumor slice culture --- tyrosine kinase inhibitors --- PPP --- ESC --- CDKN1A expression --- metastasis --- PD-L1 --- diagnostic and prognostic markers --- EVI1 --- copy number loss --- RNA sequencing --- NK cells --- glutathione metabolism --- clear cell renal cell carcinoma --- renal cell cancer --- proliferation --- eosinophilic variant --- Xp11 translocation renal cell carcinoma --- prognosis --- invasion --- immune infiltration --- IL4R? --- FISH --- 11) translocation renal cell carcinoma --- tumor microenvironment --- metabolome --- hyperosmolality --- toxicity --- ALK --- drug sensitivity --- t(6 --- copy number analysis --- urine --- genetic association --- polymorphism --- solute carrier proteins --- kidney --- metastatic ccRCC --- molecular genetic features --- recurrence-free survival --- chromophobe renal cell carcinoma --- unclassified renal tumor --- overall survival --- mTOR inhibitors --- mTOR --- JAK2 --- von Hippel–Lindau --- miR-155-5p --- glycoproteomics --- PBRM1 --- miR-133b --- survival --- TFE3 --- TFEB --- oncocytic renal tumor --- immune checkpoint inhibitors --- biomarker --- MMP10 --- TCGA --- ghrelin --- EMT like --- checkpoint inhibitors --- MiT family translocation renal cell carcinoma --- gene signature --- sarcomatoid --- transforming growth factor beta --- clear cell Renal Cell Carcinoma --- tumor adhesion --- renal cancer --- unclassified renal cell carcinoma --- Papillary renal cell carcinoma (pRCC) --- miR-146a-5p --- renal cell --- everolimus --- integrins --- cytoreductive nephrectomy --- immunotherapy --- predictive factors --- immunohistochemistry --- MTA2 --- IL13R?1 --- targeted therapy --- intratumour heterogeneity --- aurora A --- TCA cycle --- AMP-activated protein kinases --- cancer-specific survival --- programmed death-ligand 1 --- efficacy --- renal cell carcinoma --- anaplastic lymphoma kinase rearrangement --- TFEB-amplified renal cell carcinoma --- statins --- cancer immunotherapy --- microRNA --- new entity --- proteome profiling --- von Hippel-Lindau